Tumor antigen-specific CD8+ T-lymphocyte (CD8+ CTL)

Tumor antigen-specific CD8+ T-lymphocytes, also known as cytotoxic T-lymphocytes (CTLs), are a specialized subset of white blood cells crucial for the adaptive immune response against malignancies (NCI Dictionary of Cancer Terms, 2024). These cells recognize specific peptides derived from tumor-associated antigens (TAAs) or neoantigens presented by Major Histocompatibility Complex (MHC) class I molecules on the surface of cancer cells (Janeway's Immunobiology, 9th Edition). Upon activation via their T-cell receptor (TCR), they exert direct anti-tumor activity by releasing cytotoxic granules containing perforin and granzymes, which induce apoptosis in target cells (Farhood et al., Journal of Cellular Physiology, 2019). In the context of modern oncology, these cells are the primary effectors of various immunotherapies, including immune checkpoint inhibitors that relieve immunosuppression and adoptive cell therapies that involve the expansion or engineering of these cells to enhance their tumor-killing capacity (Waldman et al., Nature Reviews Immunology, 2020). Their presence and activity within the tumor microenvironment are often correlated with improved clinical outcomes and serve as a focal point for therapeutic intervention (Farhood et al., Journal of Cellular Physiology, 2019).

Other names

Cytotoxic T-lymphocyteCTLTumor-specific CD8+ T-cellTumor-infiltrating lymphocyteTIL

Therapeutic strategies involving these cells include checkpoint inhibition to prevent exhaustion, cytokine stimulation to enhance proliferation, and adoptive transfer of engineered cells (CAR-T/TCR-T) to provide direct, MHC-restricted or MHC-independent tumor cell lysis via perforin and granzyme release (Waldman et al., Nature Reviews Immunology, 2020).